Cowen Closes New Healthcare Fund

Cowen Healthcare Investments, part of the investment management division of publicly traded Cowen, has held a final closing of Cowen Healthcare Investments III LP with $493 million of capital.

The new fund, which closed above its $400 million target, received commitments from both existing and new investors, including institutional investors, family offices, and high net worth individuals.

New York City-headquartered Cowen Healthcare invests in private healthcare companies that are active in the biopharma, diagnostics and digital health sectors. The group was founded in 2012 and today is led by Managing Partner Kevin Raidy, Managing Director Tim Anderson, and Partner Robert Sine. Since 2012 the team has invested in 38 private healthcare companies.

“Investing in premier life sciences companies could not be more critical than it is today,” said Mr. Raidy. “We are extremely optimistic about the prospects of this industry to address urgent, unmet medical needs, and in doing so to transform the lives of patients and their families. We feel privileged to be able to partner with exceptional management teams and like-minded investors to help build the next generation of world-class, innovative healthcare companies.”

“As part of Cowen’s DNA, Cowen Healthcare demonstrates our organization’s ability to identify, develop, and deliver differentiated investment strategies,” said Elizabeth Flisser Rosman, a managing director and head of investment management at Cowen. “Using Cowen’s powerful platform, we look forward to developing additional investment products that meet our clients’ needs and create long-term value for all of Cowen’s stakeholders.”

Cowen (NASDAQ: COWN) is a financial services firm that provides alternative investment, investment banking, research, and sales and trading services. The firm was founded in 1918 and is headquartered in New York and has additional offices worldwide.

Private Equity Professional | May 20, 2020

Print Friendly, PDF & Email